Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/53243
Title: Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.
Author: Cruz, Nuria
Sanchez-Moreno, Jose
Torres, Ferran
Goikolea, José Manuel
Valentí Ribas, Marc
Vieta i Pascual, Eduard, 1963-
Keywords: Trastorn bipolar
Antipsicòtics
Assaigs clínics de medicaments
Placebos
Manic-depressive illness
Antipsychotic drugs
Drug testing
Placebos (Medicine)
Issue Date: 30-Mar-2010
Publisher: Cambridge University Press
Abstract: Randomized, controlled trials have demonstrated efficacy for second-generation antipsychotics in the treatment of acute mania in bipolar disorder. Despite depression being considered the hallmark of bipolar disorder, there are no published systematic reviews or meta-analyses to evaluate the efficacy of modern atypical antipsychotics in bipolar depression. We systematically reviewed published or registered randomized, double-blind, placebo-controlled trials (RCTs) of modern antipsychotics in adult bipolar I and/or II depressive patients (DSM-IV criteria). Efficacy outcomes were assessed based on changes in the Montgomery-Asberg Depression Rating Scale (MADRS) during an 8-wk period. Data were combined through meta-analysis using risk ratio as an effect size with a 95% confidence interval (95% CI) and with a level of statistical significance of 5% (p<0.05). We identified five RCTs; four involved antipsychotic monotherapy and one addressed both monotherapy and combination with an antidepressant. The two quetiapine trials analysed the safety and efficacy of two doses: 300 and 600 mg/d. The only olanzapine trial assessed olanzapine monotherapy within a range of 5-20 mg/d and olanzapine-fluoxetine combination within a range of 5-20 mg/d and 6-12 mg/d, respectively. The two aripiprazole placebo-controlled trials assessed doses of 5-30 mg/d. Quetiapine and olanzapine trials (3/5, 60%) demonstrated superiority over placebo (p<0.001). Only 2/5 (40%) (both aripiprazole trials) failed in the primary efficacy measure after the first 6 wk. Some modern antipsychotics (quetiapine and olanzapine) have demonstrated efficacy in bipolar depressive patients from week 1 onwards. Rapid onset of action seems to be a common feature of atypical antipsychotics in bipolar depression. Comment in The following popper user interface control may not be accessible. Tab to the next button to revert the control to an accessible version.Destroy user interface controlEfficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis--results to be interpreted with caution.
Note: Reproducció del document publicat a: http://dx.doi.org/10.1017/S1461145710000350
It is part of: International Journal of Neuropsychopharmacology, 2010, vol. 13, num. 7, p. 5-14
Related resource: http://dx.doi.org/10.1017/S1461145710000350
URI: http://hdl.handle.net/2445/53243
ISSN: 1461-1457
Appears in Collections:Articles publicats en revistes (Psicologia Clínica i Psicobiologia)

Files in This Item:
File Description SizeFormat 
573840.pdf107.91 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.